368.5K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Michael D. Kishbauch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Hugh M. Cole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Jonathan Violin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Joanne T. Beck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Frederick C. Callori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Sunil Agarwal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 28,200 | 28,200 | - | - | Stock Option (Right to Buy) | |
| Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. | 01 Apr 2024 | 10,000 | 10,000 (0%) | 0% | 3.9 | 38,700 | Common Stock |
| Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Morabito | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.59 per share. | 01 Apr 2024 | 10,000 | 0 (0%) | 0% | 13.6 | 135,939 | Common Stock |
| Morabito Christopher | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Noah Clauser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Milne C. Jill | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 534,600 | 534,600 | - | - | Stock Option (Right to Buy) | |
| Matthews Andrea | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Benjamin Harshbarger | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Morabito | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.02 per share. | 26 Jan 2024 | 800 | 0 (0%) | 0% | 11.0 | 8,812 | Common Stock |
| Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 800 | 99,200 | - | - | Stock Option (Right to Buy) | |
| Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 9,200 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Morabito | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. | 26 Jan 2024 | 9,200 | 9,200 (0%) | 0% | 3.9 | 35,604 | Common Stock |
| Christopher Morabito | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.15 per share. | 26 Jan 2024 | 9,200 | 0 (0%) | 0% | 11.1 | 102,552 | Common Stock |
| Morabito Christopher | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.87 per share. | 26 Jan 2024 | 800 | 800 (0%) | 0% | 3.9 | 3,096 | Common Stock |
| Michael D. Kishbauch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Hugh M. Cole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Jonathan Violin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Benjamin Harshbarger | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Noah Clauser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Joanne T. Beck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Frederick C. Callori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Andrea Matthews | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Morabito | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Andrea Matthews | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Michael D. Kishbauch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
| Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
| Hugh M. Cole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
| Jonathan Violin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
| Joanne T. Beck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
| Frederick C. Callori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 195,000 | 195,000 | - | - | Stock Option (right to buy) | |
| Benjamin Harshbarger | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Noah Clauser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Andrew Komjathy | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 6.70 per share. | 19 Nov 2021 | 100 | 100 (0%) | 0% | 6.7 | 670 | Common Stock |
| Jonathan Violin | Director | Other type of transaction at price $ 0.00 per share. | 20 Sep 2021 | 263,321 | 263,321 (0%) | 0% | 0 | Common Stock | |
| Jonathan Violin | Director | Other type of transaction at price $ 0.00 per share. | 20 Sep 2021 | 263,321 | 0 (0%) | 0% | 0 | Common Stock | |
| Benjamin Harshbarger | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Michael D. Kishbauch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Hugh M. Cole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Jonathan Violin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 1,400,000 | 1,400,000 | - | - | Stock Option (right to buy) | |
| Benjamin Harshbarger | Senior VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Noah Clauser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Joanne T. Beck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Fred Callori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Fred Callori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 1,617 | 30,920 | - | - | Series X Convertible Preferred Stock | |
| Jonathan Violin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Fred Callori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Noah Clauser | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Burt A. Adelman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Michael D. Kishbauch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Hugh M. Cole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Joanne T. Beck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | CMO; SVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Noah Clauser | Principal Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2019 | 44,500 | 44,500 | - | - | Stock Option (right to buy) | |
| Hugh M. Cole | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2019 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Burt A. Adelman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2019 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Michael D. Kishbauch | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2019 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2019 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Gregg Anthony Lapointe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2019 | 12,200 | 12,200 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | CMO; SVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2019 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Deirdre A. Cunnane | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2019 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2019 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Joanne T. Beck | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2019 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Gregg Anthony Lapointe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2019 | 2,800 | 2,800 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | CMO; SVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2018 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2018 | 230,000 | 230,000 | - | - | Stock Option (right to buy) | |
| Deirdre A. Cunnane | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2018 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Sep 2018 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2018 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Burt A. Adelman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2018 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Michael D. Kishbauch | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2018 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Jean M. George | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2018 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Michael Ross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2018 | 14,000 | 14,000 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | CMO; SVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2018 | 230,000 | 230,000 | - | - | Stock Option (right to buy) | |
| Deirdre A. Cunnane | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Edward K. Hibben | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2017 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Burt A. Adelman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2017 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Michael D. Kishbauch | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2017 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Jean M. George | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2017 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Michael Ross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2017 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | CMO; SVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Deirdre A. Cunnane | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2017 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Andrew John Nichols | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2016 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | CMO; SVP Clinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2016 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2016 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Rick Modi | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2016 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Deirdre A. Cunnane | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2016 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2016 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Nicholas G. Galakatos | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2016 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Jean M. George | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2016 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Michael Ross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2016 | 6,500 | 6,500 | - | - | Stock Option (right to buy) | |
| Burt A. Adelman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2016 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Michael D. Kishbauch | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2016 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2016 | 66,000 | 66,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2016 | 103,000 | 103,000 | - | - | Stock Option (right to buy) | |
| Ian C. Sanderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2016 | 52,000 | 52,000 | - | - | Stock Option (right to buy) | |
| Rick Modi | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2016 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| Deirdre A. Cunnane | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2016 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | |
| Jill C. Milne | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2015 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Kenneth M. Bate | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2015 | 11,094 | 11,094 | - | - | Stock Option (right to buy) | |
| Nicholas G. Galakatos | Director, Ten Percent Owner | 30 Jun 2015 | 20,800,000 | 0 | - | - | Series A Preferred Stock | ||
| Nicholas G. Galakatos | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2015 | 11,094 | 11,094 | - | - | Stock Option (right to buy) | |
| Nicholas G. Galakatos | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 30 Jun 2015 | 376,695 | 2,752,488 | - | - | Common Stock | |
| Nicholas G. Galakatos | Director, Ten Percent Owner | 30 Jun 2015 | 9,728,971 | 0 | - | - | Series B Preferred Stock | ||
| Nicholas G. Galakatos | Director, Ten Percent Owner | 30 Jun 2015 | 757,117 | 2,375,793 | - | - | Common Stock | ||
| Nicholas G. Galakatos | Director, Ten Percent Owner | 30 Jun 2015 | 1,618,676 | 1,618,676 | - | - | Common Stock | ||
| Jean M. George | None | 30 Jun 2015 | 674,446 | 674,446 | - | - | Common Stock | ||
| Jean M. George | None | 30 Jun 2015 | 3,910,392 | 0 | - | - | Series B Preferred Stock | ||
| Jean M. George | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 30 Jun 2015 | 12,422 | 90,764 | - | - | Common Stock | |
| Jean M. George | None | 30 Jun 2015 | 8,666,667 | 0 | - | - | Series A Preferred Stock | ||
| Jean M. George | None | 30 Jun 2015 | 7,388,491 | 0 | - | - | Series B Preferred Stock | ||
| Jean M. George | None | 30 Jun 2015 | 78,342 | 78,342 | - | - | Common Stock | ||
| Jean M. George | None | 30 Jun 2015 | 574,979 | 574,979 | - | - | Common Stock | ||
| Jean M. George | None | 30 Jun 2015 | 1,006,712 | 0 | - | - | Series B Preferred Stock | ||
| Jean M. George | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 30 Jun 2015 | 91,166 | 666,145 | - | - | Common Stock | |
| Jean M. George | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 30 Jun 2015 | 155,188 | 1,133,943 | - | - | Common Stock | |
| Jean M. George | None | 30 Jun 2015 | 304,309 | 978,755 | - | - | Common Stock | ||
| Jean M. George | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2015 | 11,094 | 11,094 | - | - | Stock Option (right to buy) | |
| Michael Jirousek | Chief Scientific Officer | 30 Jun 2015 | 856,571 | 0 | - | - | Series A Preferred Stock | ||
| Michael Jirousek | Chief Scientific Officer | 30 Jun 2015 | 409 | 246,093 | - | - | Common Stock | ||
| Michael Jirousek | Chief Scientific Officer | 30 Jun 2015 | 66,658 | 245,684 | - | - | Common Stock | ||
| Michael Jirousek | Chief Scientific Officer | 30 Jun 2015 | 5,261 | 0 | - | - | Series B Preferred Stock | ||
| Michael Ross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2015 | 11,094 | 11,094 | - | - | Stock Option (right to buy) | |
| Joanne M. Donovan | Chief Medical Officer | 30 Jun 2015 | 409 | 409 | - | - | Common Stock | ||
| Joanne M. Donovan | Chief Medical Officer | 30 Jun 2015 | 5,261 | 0 | - | - | Series B Preferred Stock | ||
| Jill C. Milne | Director, President and CEO | 30 Jun 2015 | 66,657 | 245,683 | - | - | Common Stock | ||
| Jill C. Milne | Director, President and CEO | 30 Jun 2015 | 856,548 | 0 | - | - | Series A Preferred Stock | ||
| Jill C. Milne | Director, President and CEO | 30 Jun 2015 | 105,229 | 0 | - | - | Series B Preferred Stock | ||
| Jill C. Milne | Director, President and CEO | 30 Jun 2015 | 8,189 | 253,872 | - | - | Common Stock | ||
| Rick Modi | Chief Business Officer | 30 Jun 2015 | 52,614 | 0 | - | - | Series B Preferred Stock | ||
| Rick Modi | Chief Business Officer | 30 Jun 2015 | 4,094 | 4,094 | - | - | Common Stock | ||
| Ron Laufer | Director, Ten Percent Owner | 30 Jun 2015 | 1,079,115 | 1,079,115 | - | - | Common Stock | ||
| Ron Laufer | Director, Ten Percent Owner | 30 Jun 2015 | 13,866,666 | 0 | - | - | Series A Preferred Stock | ||
| Ron Laufer | Director, Ten Percent Owner | 30 Jun 2015 | 4,241,780 | 0 | - | - | Series B Preferred Stock | ||
| Ron Laufer | Director, Ten Percent Owner | 30 Jun 2015 | 330,098 | 1,409,213 | - | - | Common Stock | ||
| Ron Laufer | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 30 Jun 2015 | 223,439 | 1,632,652 | - | - | Common Stock | |
| Ron Laufer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2015 | 11,094 | 11,094 | - | - | Stock Option (right to buy) |